Vol 17, No 3 (2020)
Review paper
Get Citation

Second generation antipsychotics in the therapy of patients with negative symptoms of schizophrenia

Agata Szulc
DOI: 10.5603/PSYCH.2020.0030
·
Psychiatria 2020;17(3):134-144.

paid access

Vol 17, No 3 (2020)
Prace poglądowe - nadesłane

Abstract

The pharmacotherapy of schizophrenia, and particularly its negative symptoms, is a difficult and complex process. It is
necessary to properly identify groups of patients, and especially individual patients, depending on the nature of negative
symptoms, i.e. whether they are primary or secondary, predominant or significant, or predominant and persistent.
The literature regarding the efficacy of various second-generation antipsychotics in the treatment of negative symptoms
is not uniform; the assessment of negative symptoms is based on different methods, and the studies involve diversified
patient groups where patients’ responses to the studied drugs probably vary depending on whether their negative
symptoms are significant, predominant or predominant and persistent. Moreover, a vast majority of studies concern the
general population of schizophrenic patients, where the intensity of negative symptoms was evaluated amongst other
parameters. All of these factors make it practically impossible to evaluate and compare these studies. In addition, the
selection of a second-generation anti-psychotic that would show superiority over others is also difficult.
As a part of this study, a review of the literature for randomized trials directly comparing second-generation key antipsychotics
used in the treatment of negative symptoms was performed. In most of the analyzed studies, no statistically
significant differences were found between the analyzed drugs (comparison of risperidone, amisulpride, aripiprazole,
and olanzapine between them). Only individual studies have shown that olanzapine is superior to risperidone in assessing
the effect of both drugs on negative symptoms. However, it should be emphasized that the results were characterized
by limited credibility in terms of the possibility of drawing conclusions about the direct influence of drugs on negative
symptoms. The reason for this state of affairs should be sought, i.a. in the fact that in these studies the obtained effects
were not adjusted for the confounding factors whose influence on negative symptoms was confirmed. However in
patients with predominant and persistent negative symptoms cariprazine is superior to risperidone.
Complementary analysis of secondary studies for the analysed drugs indicated greater efficacy of second-generation
antipsychotics over first-generation drugs and placebo in various groups of patients with negative symptoms.
It must be underlined, however, that these studies are difficult to compare due to their non-homogeneity.
Another problem that arises in the context of clinical trials and daily practice it the proper diagnosis and differentiation
of primary negative symptoms from secondary negative symptoms.

Abstract

The pharmacotherapy of schizophrenia, and particularly its negative symptoms, is a difficult and complex process. It is
necessary to properly identify groups of patients, and especially individual patients, depending on the nature of negative
symptoms, i.e. whether they are primary or secondary, predominant or significant, or predominant and persistent.
The literature regarding the efficacy of various second-generation antipsychotics in the treatment of negative symptoms
is not uniform; the assessment of negative symptoms is based on different methods, and the studies involve diversified
patient groups where patients’ responses to the studied drugs probably vary depending on whether their negative
symptoms are significant, predominant or predominant and persistent. Moreover, a vast majority of studies concern the
general population of schizophrenic patients, where the intensity of negative symptoms was evaluated amongst other
parameters. All of these factors make it practically impossible to evaluate and compare these studies. In addition, the
selection of a second-generation anti-psychotic that would show superiority over others is also difficult.
As a part of this study, a review of the literature for randomized trials directly comparing second-generation key antipsychotics
used in the treatment of negative symptoms was performed. In most of the analyzed studies, no statistically
significant differences were found between the analyzed drugs (comparison of risperidone, amisulpride, aripiprazole,
and olanzapine between them). Only individual studies have shown that olanzapine is superior to risperidone in assessing
the effect of both drugs on negative symptoms. However, it should be emphasized that the results were characterized
by limited credibility in terms of the possibility of drawing conclusions about the direct influence of drugs on negative
symptoms. The reason for this state of affairs should be sought, i.a. in the fact that in these studies the obtained effects
were not adjusted for the confounding factors whose influence on negative symptoms was confirmed. However in
patients with predominant and persistent negative symptoms cariprazine is superior to risperidone.
Complementary analysis of secondary studies for the analysed drugs indicated greater efficacy of second-generation
antipsychotics over first-generation drugs and placebo in various groups of patients with negative symptoms.
It must be underlined, however, that these studies are difficult to compare due to their non-homogeneity.
Another problem that arises in the context of clinical trials and daily practice it the proper diagnosis and differentiation
of primary negative symptoms from secondary negative symptoms.

Get Citation

Keywords

schizophrenia, negative symptoms, second generation antipsychotics

About this article
Title

Second generation antipsychotics in the therapy of patients with negative symptoms of schizophrenia

Journal

Psychiatria (Psychiatry)

Issue

Vol 17, No 3 (2020)

Article type

Review paper

Pages

134-144

DOI

10.5603/PSYCH.2020.0030

Bibliographic record

Psychiatria 2020;17(3):134-144.

Keywords

schizophrenia
negative symptoms
second generation antipsychotics

Authors

Agata Szulc

References (67)
  1. Szulc A, Samochowiec J, Gałecki P, et al. Recommendations for the treatment of schizophrenia with negative symptoms. Standards of pharmacotherapy by the Polish Psychiatric Association (Polskie Towarzystwo Psychiatryczne), part 1. Psychiatria Polska. 2019; 53(3): 497–524.
  2. Kirkpatrick B, Mucci A, Galderisi S. Primary, Enduring Negative Symptoms: An Update on Research. Schizophr Bull. 2017; 43(4): 730–736.
  3. Marder SR, Alphs L, Anghelescu IG, et al. Issues and perspectives in designing clinical trials for negative symptoms in schizophrenia. Schizophr Res. 2013; 150(2-3): 328–333.
  4. Szulc A, Dudek D, Samochowiec J, et al. Recommendations for the treatment of schizophrenia with negative symptoms. Standards of pharmacotherapy by the Polish Psychiatric Association (Polskie Towarzystwo Psychiatryczne), part 2. Psychiatria Polska. 2019; 53(3): 525–540.
  5. Feldman PD, Kaiser CJ, Kennedy JS, et al. Comparison of risperidone and olanzapine in the control of negative symptoms of chronic schizophrenia and related psychotic disorders in patients aged 50 to 65 years. J Clin Psychiatry. 2003; 64(9): 998–1004.
  6. Gurpegui M, Alvarez E, Bousoño M, et al. A randomized, 1-year follow-up study of olanzapine and risperidone in the treatment of negative symptoms in outpatients with schizophrenia. J Clin Psychopharmacol. 2006; 26(3): 238–249.
  7. Chrzanowski WK, Marcus RN, Torbeyns A, et al. Effectiveness of long-term aripiprazole therapy in patients with acutely relapsing or chronic, stable schizophrenia: a 52-week, open-label comparison with olanzapine. Psychopharmacology (Berl). 2006; 189(2): 259–266.
  8. Lecrubier Y, Quintin P, Bouhassira M, et al. The treatment of negative symptoms and deficit states of chronic schizophrenia: olanzapine compared to amisulpride and placebo in a 6-month double-blind controlled clinical trial. Acta Psychiatr Scand. 2006; 114(5): 319–327.
  9. Pigott TA, Carson WH, Saha AR, et al. Aripiprazole Study Group. Aripiprazole for the prevention of relapse in stabilized patients with chronic schizophrenia: a placebo-controlled 26-week study. J Clin Psychiatry. 2003; 64(9): 1048–1056.
  10. Németh G, Laszlovszky I, Czobor P, et al. Cariprazine versus risperidone monotherapy for treatment of predominant negative symptoms in patients with schizophrenia: a randomised, double-blind, controlled trial. Lancet. 2017; 389(10074): 1103–1113.
  11. Gómez-Revuelta M, Pelayo-Terán JM, Juncal-Ruiz M, et al. Antipsychotic Treatment Effectiveness in First Episode of Psychosis: PAFIP 3-Year Follow-Up Randomized Clinical Trials Comparing Haloperidol, Olanzapine, Risperidone, Aripiprazole, Quetiapine, and Ziprasidone. Int J Neuropsychopharmacol. 2020; 23(4): 217–229.
  12. Cheng Z, Yuan Y, Han X, et al. An open-label randomised comparison of aripiprazole, olanzapine and risperidone for the acute treatment of first-episode schizophrenia: Eight-week outcomes. J Psychopharmacol. 2019; 33(10): 1227–1236.
  13. Lestari ET, Effendy E, Amin MM, et al. The Comparison of Olanzapine and Risperidone Treatment in Male Schizophrenic Patients using Positive and Negative Syndromes Scale (PANSS). Open Access Maced J Med Sci. 2018; 6(4): 638–642.
  14. Suresh Kumar PN, Anish PK, Rajmohan V. Olanzapine has better efficacy compared to risperidone for treatment of negative symptoms in schizophrenia. Indian J Psychiatry. 2016; 58(3): 311–316.
  15. Shoja Shafti S, Gilanipoor M. A Comparative Study between Olanzapine and Risperidone in the Management of Schizophrenia. Schizophr Res Treatment. 2014; 2014: 307202.
  16. Chen JJ, Chan HY, Chen CH, et al. Risperidone and olanzapine versus another first generation antipsychotic in patients with schizophrenia inadequately responsive to first generation antipsychotics. Pharmacopsychiatry. 2012; 45(2): 64–71.
  17. Crespo-Facorro B, Pérez-Iglesias R, Mata I, et al. Effectiveness of haloperidol, risperidone and olanzapine in the treatment of first-episode non-affective psychosis: results of a randomized, flexible-dose, open-label 1-year follow-up comparison. J Psychopharmacol. 2011; 25(6): 744–754.
  18. Crespo-Facorro B, Pérez-Iglesias R, Mata I, et al. Long-term (3-year) effectiveness of haloperidol, risperidone and olanzapine: results of a randomized, flexible-dose, open-label comparison in first-episode nonaffective psychosis. Psychopharmacology (Berl). 2012; 219(1): 225–233.
  19. Ritchie CW, Chiu E, Harrigan S, et al. A comparison of the efficacy and safety of olanzapine and risperidone in the treatment of elderly patients with schizophrenia: an open study of six months duration. Int J Geriatr Psychiatry. 2006; 21(2): 171–179.
  20. Cuesta MJ, Jalón EG, Campos MS, et al. Cognitive effectiveness of olanzapine and risperidone in first-episode psychosis. Br J Psychiatry. 2009; 194(5): 439–445.
  21. Hatta K, Sato K, Hamakawa H, et al. Effectiveness of second-generation antipsychotics with acute-phase schizophrenia. Schizophr Res. 2009; 113(1): 49–55.
  22. Sacchetti E, Valsecchi P, Parrinello G, et al. QUERISOLA Group. A randomized, flexible-dose, quasi-naturalistic comparison of quetiapine, risperidone, and olanzapine in the short-term treatment of schizophrenia: the QUERISOLA trial. Schizophr Res. 2008; 98(1-3): 55–65.
  23. Keefe RSE, Sweeney JA, Gu H, et al. Efficacy and tolerability of olanzapine, quetiapine, and risperidone in the treatment of early psychosis: a randomized, double-blind 52-week comparison. Am J Psychiatry. 2007; 164(7): 1050–1060.
  24. Stroup TS, Lieberman JA, McEvoy JP, et al. CATIE Investigators. Effectiveness of olanzapine, quetiapine, risperidone, and ziprasidone in patients with chronic schizophrenia following discontinuation of a previous atypical antipsychotic. Am J Psychiatry. 2006; 163(4): 611–622.
  25. Keefe RSE, Young CA, Rock SL, et al. HGGN Study Group. One-year double-blind study of the neurocognitive efficacy of olanzapine, risperidone, and haloperidol in schizophrenia. Schizophr Res. 2006; 81(1): 1–15.
  26. Stroup TS, Lieberman JA, McEvoy JP, et al. CATIE Investigators. Effectiveness of olanzapine, quetiapine, and risperidone in patients with chronic schizophrenia after discontinuing perphenazine: a CATIE study. Am J Psychiatry. 2007; 164(3): 415–427.
  27. Wang X, Savage R, Borisov A, et al. Efficacy of risperidone versus olanzapine in patients with schizophrenia previously on chronic conventional antipsychotic therapy: a switch study. J Psychiatr Res. 2006; 40(7): 669–676.
  28. Gureje O, Miles W, Keks N, et al. Olanzapine vs risperidone in the management of schizophrenia: a randomized double-blind trial in Australia and New Zealand. Schizophr Res. 2003; 61(2-3): 303–314.
  29. van Bruggen J, Tijssen J, Dingemans P, et al. Symptom response and side-effects of olanzapine and risperidone in young adults with recent onset schizophrenia. Int Clin Psychopharmacol. 2003; 18(6): 341–346.
  30. Conley RR, Mahmoud R. A randomized double-blind study of risperidone and olanzapine in the treatment of schizophrenia or schizoaffective disorder. Am J Psychiatry. 2001; 158(5): 765–774.
  31. Purdon SE, Jones BD, Stip E, et al. Neuropsychological change in early phase schizophrenia during 12 months of treatment with olanzapine, risperidone, or haloperidol. The Canadian Collaborative Group for research in schizophrenia. Arch Gen Psychiatry. 2000; 57(3): 249–258.
  32. Tran PV, Hamilton SH, Kuntz AJ, et al. Double-blind comparison of olanzapine versus risperidone in the treatment of schizophrenia and other psychotic disorders. J Clin Psychopharmacol. 1997; 17(5): 407–418.
  33. Robinson DG, Gallego JA, John M, et al. A Randomized Comparison of Aripiprazole and Risperidone for the Acute Treatment of First-Episode Schizophrenia and Related Disorders: 3-Month Outcomes. Schizophr Bull. 2015; 41(6): 1227–1236.
  34. Li H, Luo J, Wang C, et al. Efficacy and safety of aripiprazole in Chinese Han schizophrenia subjects: a randomized, double-blind, active parallel-controlled, multicenter clinical trial. Schizophr Res. 2014; 157(1-3): 112–119.
  35. Sato G, Yoshimura S, Yamashita H, et al. The neurocognitive effects of aripiprazole compared with risperidone in the treatment of schizophrenia. Hiroshima J Med Sci. 2012; 61(4): 75–83.
  36. Liemburg E, Aleman A, Bous J, et al. An open randomized pilot trial on the differential effects of aripiprazole versus risperidone on anhedonia and subjective well-being. Pharmacopsychiatry. 2011; 44(3): 109–113.
  37. Chan HY, Lin WW, Lin SK, et al. Efficacy and safety of aripiprazole in the acute treatment of schizophrenia in Chinese patients with risperidone as an active control: a randomized trial. J Clin Psychiatry. 2007; 68(1): 29–36.
  38. Hwang TJ, Lee SM, Sun HJ, et al. Amisulpride versus risperidone in the treatment of schizophrenic patients: a double-blind pilot study in Taiwan. J Formos Med Assoc. 2003; 102(1): 30–36.
  39. Sechter D, Peuskens J, Fleurot O, et al. Amisulpride Study Group. Amisulpride vs. risperidone in chronic schizophrenia: results of a 6-month double-blind study. Neuropsychopharmacology. 2002; 27(6): 1071–1081.
  40. Peuskens J, Bech P, Möller HJ, et al. Amisulpride vs. risperidone in the treatment of acute exacerbations of schizophrenia. Amisulpride study group. Psychiatry Res. 1999; 88(2): 107–117.
  41. Kane JM, Osuntokun O, Kryzhanovskaya LA, et al. A 28-week, randomized, double-blind study of olanzapine versus aripiprazole in the treatment of schizophrenia. J Clin Psychiatry. 2009; 70(4): 572–581.
  42. Pawar GR, Phadnis P, Paliwal A. Evaluation of efficacy, safety, and cognitive profile of amisulpride per se and its comparison with olanzapine in newly diagnosed schizophrenic patients in an 8-week, double-blind, single-centre, prospective clinical trial. ISRN Psychiatry. 2012; 2012: 703751.
  43. Bhowmick S, Hazra A, Ghosh M. Amisulpride versus olanzapine in the treatment of schizophrenia in Indian patients: randomized controlled trial. Aust N Z J Psychiatry. 2010; 44(3): 237–242.
  44. Quednow BB, Wagner M, Westheide J, et al. Cognitive improvement in schizophrenic patients does not require a serotonergic mechanism: randomized controlled trial of olanzapine vs amisulpride. Neuropsychopharmacology. 2005; 30(2): 381–390.
  45. Mortimer A, Martin S, Lôo H, et al. SOLIANOL Sudy Group. A double-blind, randomized comparative trial of amisulpride versus olanzapine for 6 months in the treatment of schizophrenia. Int Clin Psychopharmacol. 2004; 19(2): 63–69.
  46. Tollefson GD, Sanger TM. Negative symptoms: a path analytic approach to a double-blind, placebo- and haloperidol-controlled clinical trial with olanzapine. Am J Psychiatry. 1997; 154(4): 466–474.
  47. Krause M, Zhu Y, Huhn M, et al. How well do patients with a first episode of schizophrenia respond to antipsychotics: A systematic review and meta-analysis. Eur Neuropsychopharmacol. 2017; 27(9): 835–844.
  48. Boyer P, Lecrubier Y, Puech AJ, et al. Treatment of negative symptoms in schizophrenia with amisulpride. Br J Psychiatry. 1995; 166(1): 68–72.
  49. Danion JM, Rein W, Fleurot O. Improvement of schizophrenic patients with primary negative symptoms treated with amisulpride. Amisulpride Study Group. Am J Psychiatry. 1999; 156(4): 610–616.
  50. Loo H, Poirier-Littre MF, Theron M, et al. Amisulpride versus placebo in the medium-term treatment of the negative symptoms of schizophrenia. Br J Psychiatry. 1997; 170: 18–22.
  51. Fusar-Poli P, Papanastasiou E, Stahl D, et al. Treatments of Negative Symptoms in Schizophrenia: Meta-Analysis of 168 Randomized Placebo-Controlled Trials. Schizophr Bull. 2015; 41(4): 892–899.
  52. Leucht S, Arbter D, Engel RR, et al. How effective are second-generation antipsychotic drugs? A meta-analysis of placebo-controlled trials. Mol Psychiatry. 2009; 14(4): 429–447.
  53. Paillère-Martinot ML, Lecrubier Y, Martinot JL, et al. Improvement of some schizophrenic deficit symptoms with low doses of amisulpride. Am J Psychiatry. 1995; 152(1): 130–134.
  54. Leucht S, Corves C, Arbter D, et al. Second-generation versus first-generation antipsychotic drugs for schizophrenia: a meta-analysis. Lancet. 2009; 373(9657): 31–41.
  55. Rummel-Kluge C, Komossa K, Schwarz S, et al. A meta-analysis of head-to-head comparisons of second-generation antipsychotics in the treatment of schizophrenia. Am J Psychiatry. 2009; 166(2): 152–163.
  56. Lindenmayer JP, Khan A, Iskander A, et al. A randomized controlled trial of olanzapine versus haloperidol in the treatment of primary negative symptoms and neurocognitive deficits in schizophrenia. J Clin Psychiatry. 2007; 68(3): 368–379.
  57. Buchanan RW, Panagides J, Zhao J, et al. Asenapine versus olanzapine in people with persistent negative symptoms of schizophrenia. J Clin Psychopharmacol. 2012; 32(1): 36–45.
  58. Kinon BJ, Noordsy DL, Liu-Seifert H, et al. Randomized, double-blind 6-month comparison of olanzapine and quetiapine in patients with schizophrenia or schizoaffective disorder with prominent negative symptoms and poor functioning. J Clin Psychopharmacol. 2006; 26(5): 453–461.
  59. Sirota P, Pannet I, Koren A, et al. Quetiapine versus olanzapine for the treatment of negative symptoms in patients with schizophrenia. Hum Psychopharmacol. 2006; 21(4): 227–234.
  60. Ciudad A, Olivares JM, Bousoño M, et al. A randomized, 1-year follow-up study of olanzapine and risperidone in the treatment of negative symptoms in outpatients with schizophrenia. J Clin Psychopharmacol. 2006; 26(3): 238–249.
  61. Riedel M, Müller N, Strassnig M, et al. Quetiapine has equivalent efficacy and superior tolerability to risperidone in the treatment of schizophrenia with predominantly negative symptoms. Eur Arch Psychiatry Clin Neurosci. 2005; 255(6): 432–437.
  62. Ruhrmann S, Kissling W, Lesch OM, et al. Efficacy of flupentixol and risperidone in chronic schizophrenia with predominantly negative symptoms. Prog Neuropsychopharmacol Biol Psychiatry. 2007; 31(5): 1012–1022.
  63. Hanson E, Healey K, Wolf D, et al. Assessment of Pharmacotherapy for Negative Symptoms of Schizophrenia. Current Psychiatry Reports. 2010; 12(6): 563–571.
  64. Wójciak P, Rybakowski J. Clinical picture, pathogenesis and psychometric assessment of negative symptoms of schizophrenia. Psychiatria Polska. 2018; 52(2): 185–197.
  65. Wójciak P, Domowicz K, Rybakowski J. Objawy negatywne schizofrenii pierwotne i wtórne, zespół deficytowy, uporczywe objawy negatywne. Neuropsychiatria i Neuropsychologia. 2017; 12(3): 108–117.
  66. Chiappelli J, Nugent KL, Thangavelu K, et al. Assessment of trait and state aspects of depression in schizophrenia. Schizophr Bull. 2014; 40(1): 132–142.
  67. Huang M, Huang Yi, Yu L, et al. Relationship between negative symptoms and neurocognitive functions in adolescent and adult patients with first-episode schizophrenia. BMC Psychiatry. 2016; 16(1): 344.

Important: This website uses cookies. More >>

The cookies allow us to identify your computer and find out details about your last visit. They remembering whether you've visited the site before, so that you remain logged in - or to help us work out how many new website visitors we get each month. Most internet browsers accept cookies automatically, but you can change the settings of your browser to erase cookies or prevent automatic acceptance if you prefer.

Wydawcą serwisu jest Via Medica sp. z o.o. sp. komandytowa, ul. Świętokrzyska 73, 80–180 Gdańsk

tel.:+48 58 320 94 94, faks:+48 58 320 94 60, e-mail:  viamedica@viamedica.pl